Following years of clinical validation and proven real-world performance at Saint Göran, Stockholm Region adopts Lunit INSIGHT MMG as an independent second reader at regional scale

Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology,  announced that its AI-powered mammography solution, Lunit INSIGHT MMG, will be implemented as an independent second reader across the entire Stockholm Region in Sweden, building on years of successful clinical validation and real-world use at Capio Saint Göran Hospital.

The Stockholm deployment follows Lunit's earlier regional deployment in Dalarna, marking the company's second region-level deployment in Sweden. It builds on several years of clinical and operational experience at Saint Göran, where the solution progressed from prospective clinical evaluation to routine breast cancer screening. Since its adoption in 2023, Lunit's AI solution has supported approximately 200,000 examinations over the past three years and has continued to support the screening workflow through changes in mammography systems, demonstrating its ability to operate at scale in a real-world screening environment.

That track record began with ScreenTrustCAD, a prospective population-based study at Saint Göran that evaluated the solution in the real-world screening of more than 55,000 women. One-year real-world results presented at the Radiological Society of North America (RSNA) 2024 Annual Meeting later showed a 15% increase in cancer detection and more than a 36% reduction in radiologists' reading time, with strong Normal Flagging performance contributing to improved reading efficiency.

"Building on this progression from clinical research to routine implementation and real-world validation, the expansion across Stockholm Region represents an important next step," said Karin Dembrower of Capio Saint Göran Hospital. "It brings an approach first evaluated and implemented at a single hospital to a broader regional breast cancer screening environment."

"Stockholm is a powerful example of how rigorous clinical evidence can translate into real-world adoption and ultimately broader healthcare implementation," said Brandon Suh, CEO of Lunit. "What began as a prospective clinical study has grown into routine clinical use and is now expanding to a regional scale. We believe this evidence-to-adoption journey demonstrates the role clinically validated AI can play in building more effective and sustainable cancer screening programs worldwide."

The Stockholm Region deployment marks another important milestone in Lunit's expansion across Europe, demonstrating how clinical evidence, real-world validation, and routine implementation can translate into large-scale adoption of AI in population-based breast cancer screening.